Across TCGA pan-cancer cohorts, BTN3A2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BTN3A2 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher BTN3A2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTN3A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and HNSC are the cancer types where BTN3A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	30	view →
UCEC	DFS	Median	All	0.962	0.619	.013	8	view →
HNSC	OS	Median	All	0.177	0.710	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: BTN3A2 tumor-vs-normal RNA expression · all BTN3A2 data types